SAGE Sage Therapeutics Inc.

+4.92  (+3%)
Previous Close 171.03
Open 169.75
Price To Book 6.82
Market Cap 8999437463
Shares 51,147,698
Volume 494,172
Short Ratio
Av. Daily Volume 482,446

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA approval announced March 19, 2018.
Brexanolone - SAGE-547 (202C)
Postpartum Depression - moderate
Phase 3 data due 4Q 2019 or 1Q 2020.
Major Depressive Disorder (MDD)
Phase 3 data met primary endpoint - January 7, 2019.
Postpartum depression (PPD)
Phase 3 data released November 9, 2017. Primary endpoint met.
Brexanolone - SAGE-547 (202B)
Postpartum Depression (Severe)
Phase 3 data released September 12, 2017 - primary endpoint not met.
Phase 3 data due 2020.
Phase 2 Part A data due July 2019.
Bipolar depression
Phase 1 biomarker data due 1H 2019 with Huntington’s Disease Phase 1 cohort data due 2H 2019.
Huntington's disease
Phase 1 MAD data due July 2019. Top-line data due 2H 2019.
Essential tremor
Phase 3 data due 2020.
Major Depressive Disorder (MDD)

Latest News

  1. Are Investors Undervaluing Sage Therapeutics, Inc. (NASDAQ:SAGE) By 29%?
  2. Ligand Grants Preclinical Candidate Rights to UK-based Firm
  3. Sage Therapeutics to Present at 2019 RBC Capital Markets Global Healthcare Conference
  4. Edited Transcript of SAGE earnings conference call or presentation 2-May-19 12:00pm GMT
  5. New England Venture Capital Association names 2019 NEVY Awards winners
  6. Small-Cap Stocks to Watch in May
  7. Sage Therapeutics to Present at Bank of America Merrill Lynch 2019 Health Care Conference
  8. See what the IHS Markit Score report has to say about SAGE Therapeutics Inc.
  9. Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  10. Sage Therapeutics Announces First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress
  11. SAGE Therapeutics, Inc. to Host Earnings Call
  12. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Directors of Sage Therapeutics, Inc.
  13. Sage Therapeutics' Zulresso is a big win for postpartum depression sufferers — and maybe even the entire mental health community
  14. How a failed epilepsy drug became a $34,000 postpartum cure
  15. Analysts point to potential Biogen M&A options after Alzheimer's failure
  16. Did Hedge Funds Drop The Ball On SAGE Therapeutics Inc (SAGE) ?
  17. Sage Therapeutics to Report First Quarter 2019 Financial Results on Thursday, May 2, 2019
  18. The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage